Table 1.
18F-FDG imaging of sterile inflammatory diseases.
| Diseases | Study type | References | Tracers | Remarks |
|---|---|---|---|---|
| Atherosclerotic inflammation |
Clinical | Li, 2012 11 | 18F-FDG, 68Ga-DOTATATE ( PET/CT) | In patients with neuroendocrine tumors or thyroid cancer |
| Preclinical | Silvola, 2011 12 | 18F-FDG, 68Ga (microPET/CT) | In LDLR-/- ApoB100/100 mice | |
| Clinical | Yarasheski, 2012 13 | 18F-FDG (PET/CT) | In HIV-infected patients | |
| Vasculitis | Clinical | Bissonnette, 2012 14 | 18F-FDG (PET/CT) | In psoriasis patients |
| Clinical | Maki-Petaja, 2012 15 | 18F-FDG (PET/CT) | Anti-TNF therapy, in rheumatoid arthritis patients | |
| Clinical | Tegler, 2012 16 | 18F-FDG (PET/CT) | Aortic aneurysms | |
| Clinical | Tezuka, 2012 17 | 18F-FDG (PET/CT) | Takayasu arteritis | |
| Clinical | Sarda-Mantel, 2012 18 | 18F-FDG, 18F-DPA714, 18F-FCH (PET) | Abdominal aneurysms | |
| Clinical | Kim, 2010 19 | 18F-FDG (PET/CT) | In T2DM patients | |
| Valvular inflammation | Clinical | Dweck, 2012 20 | 18F-FDG, 18F-NaF (PET/CT) | |
| Arthritis | Preclinical | Irmler, 2010 21 | 18F-FDG (PET/CT) | With etanercept therapy |
| Clinical | Yamashita, 2012 22 | 18F-FDG (PET/CT) | Differentiation among PMR, SpA and RA | |
| Skin inflammation | Preclinical | McLarty, 2011 23 | 18F-FDG, 18F-scyllo-inositol (microPET) | |
| Preclinical | Autio, 2010 24 | 18F-FDG, 68Ga-DOTAVAP-P1 (animal/brain PET) | ||
| Bone inflammation | Preclinical | Brown, 2012 25 | 18F-FDG (microPET) | Differentiation with osteomyelitis |
| Myocardial inflammation |
Clinical | Lee, 2012 26 | 18F-FDG (PET/MR) | Post-myocardial infarction |
TNF: tumor necrosis factor T2DM: Type 2 Diabetes Mellitus RA: rheumatoid arthritis PMR: polymyalgia rheumatic SpA: seronegative spondyloarthritis.